SIGY Sigyn Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1642159 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY19.3%
TTM EPS YoY39.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,144.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets4,464.7%
Debt / equity—
Current ratio0.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio-811.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $773,279 | $798,165 | $657,657 | $734,014 | $419,362 |
| SG&A expense | $1.74M | $1.66M | $1.49M | $1.27M | $496,367 |
| Operating income | -$2.52M | -$2.46M | -$2.15M | -$2.01M | -$916,434 |
| Interest expense | — | — | — | $30,800 | $343,156 |
| Pretax income | -$3.34M | -$4.15M | -$2.93M | -$3.00M | -$1.26M |
| Net income | -$3.34M | -$4.15M | -$2.93M | -$3.00M | -$1.26M |
| EBITDA | -$2.51M | -$2.45M | -$2.14M | -$2.01M | -$916,088 |
| EPS (basic) | -2.51 | -3.77 | -3.13 | -0.08 | -0.17 |
| EPS (diluted) | -2.51 | -3.77 | -3.13 | -0.08 | -0.17 |
| Weighted avg. shares (diluted) | 1.33M | 1.10M | 934,915 | 36.40M | 7.35M |
| Balance sheet | |||||
| Cash & equivalents | $12,144 | $11,690 | $8,356 | $340,956 | $84,402 |
| Inventory | — | $50,000 | $50,000 | $50,000 | $586,047 |
| Current assets | $21,244 | $118,063 | $70,298 | $393,031 | $670,449 |
| PP&E, net | $9,685 | $15,296 | $22,052 | $28,046 | $1,728 |
| Intangibles | — | — | $2,100 | $5,700 | $21,905 |
| Total assets | $213,719 | $321,806 | $332,879 | $710,259 | $694,082 |
| Current liabilities | $4.61M | $3.61M | $2.05M | $734,218 | $594,903 |
| Short-term debt | $0 | — | — | — | — |
| Long-term debt | $2.02M | $2.51M | $2.28M | — | — |
| Total debt | $2.02M | $2.51M | $2.28M | — | — |
| Total liabilities | $4.67M | $3.73M | $2.24M | $974,843 | $594,903 |
| Shareholders' equity | -$4.46M | -$3.41M | -$1.90M | -$264,584 | $99,179 |
| Net debt | $2.01M | $2.50M | $2.27M | — | — |
| Shares outstanding | 1.61M | 1.29M | 956,595 | 37.30M | 35.20M |
| Cash flow statement | |||||
| Operating cash flow | -$872,436 | -$1.38M | -$1.83M | -$1.77M | -$829,809 |
| Capital expenditure | — | — | $860 | $29,264 | — |
| Free cash flow | — | — | -$1.83M | -$1.80M | — |
| Investing cash flow | — | — | -$860 | -$29,264 | -$10,799 |
| Financing cash flow | $872,890 | $1.39M | $1.50M | $2.06M | $925,010 |
| Depreciation & amortization | $5,611 | $6,756 | $6,854 | $2,946 | $346 |
| Stock-based compensation | $150,000 | $215,558 | — | — | $0 |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.